Edwards Lifesciences Raises 2026 Guidance After Strong Q1 TMTT Sales Hit $173 Million

Key Takeaways

• Edwards Lifesciences reported Q1 2026 TMTT sales of $173 million, driven by repair and replacement therapies
• Company raised full-year 2026 constant currency sales growth guidance to 9-11% from previous 8-10%
• Q1 adjusted earnings per share reached $0.78, exceeding expectations and supporting increased outlook

---

Edwards Lifesciences Beats Q1 Expectations, Raises 2026 Outlook

Edwards Lifesciences Corporation (NYSE: EW) reported stronger-than-expected first quarter 2026 results on April 23, with transcatheter mitral and tricuspid therapies (TMTT) sales reaching $173 million and prompting the medical device company to raise its full-year guidance.

The Irvine, California-based company posted Q1 earnings per share of $0.66, with adjusted EPS of $0.78. The strong performance was primarily driven by growth in repair and replacement therapies within the TMTT segment, reflecting increased adoption of Edwards’ structural heart technologies.

Guidance Upgrade Reflects Market Confidence

Based on the robust first quarter performance, Edwards Lifesciences increased its fiscal year 2026 constant currency sales growth guidance to 9% to 11%, up from the previously projected 8% to 10%. The company also raised its adjusted EPS guidance midpoint, signaling management’s confidence in sustained momentum throughout the year.

The TMTT business continues to be a key growth driver for Edwards, as the company expands its portfolio of minimally invasive heart valve therapies. The $173 million in quarterly TMTT sales represents significant progress in the structural heart disease treatment market, where Edwards competes with companies like Medtronic and Abbott.

Market Impact and Future Outlook

The guidance raise comes as Edwards continues to invest in clinical trials and regulatory approvals for next-generation transcatheter heart valve technologies. The company’s strong financial position supports ongoing research and development efforts aimed at expanding treatment options for patients with structural heart disease.

Analysts view the results positively, noting that the TMTT growth trajectory aligns with the aging global population and increasing preference for minimally invasive cardiac procedures over traditional open-heart surgery.

---

Frequently Asked Questions

What are TMTT therapies and why are they important?

TMTT (transcatheter mitral and tricuspid therapies) are minimally invasive treatments for heart valve diseases that don’t require open-heart surgery, offering patients faster recovery times and reduced surgical risks.

What does the guidance raise mean for Edwards Lifesciences stock?

The increased guidance from 8-10% to 9-11% sales growth suggests stronger business momentum and typically indicates positive investor sentiment, though individual investment decisions should consider multiple factors.

How does Edwards compare to competitors in the structural heart market?

Edwards is a leading player in transcatheter heart valve therapies, competing primarily with Medtronic and Abbott, with strong market positions in both aortic and mitral valve replacement technologies.

Related coverage

• Eli Lilly raises 2026 revenue guidance on Mounjaro demand
• Sanofi pipeline pdf: Dupixent, Lantus and 2026 catalysts
• GSK’s Blenrep returns to the US market after FDA approves resubmission